Peter Ruane
0000-0002-7170-9928
Publication & Citation Trends
Publications
0 total
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Cited by 68
Semantic Scholar
Efx treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis to a similar extent in NASH patients with high-risk PNPLA3 genotypes, compared to those with lowest genetic risk: a post-hoc analysis of balanced study
Cited by 1
Semantic Scholar
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial
Cited by 13
Semantic Scholar
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis OA
Cited by 88
Semantic Scholar
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. OA
Cited by 39
Semantic Scholar
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Cited by 92
Semantic Scholar
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. OA
Cited by 168
Semantic Scholar
The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH
Cited by 1
Semantic Scholar
Research Topics
HIV/AIDS drug development and treatment
(84)
HIV Research and Treatment
(56)
Hepatitis C virus research
(43)
HIV/AIDS Research and Interventions
(36)
Liver Disease Diagnosis and Treatment
(26)
Affiliations
Cedars-Sinai Medical Center
West Los Angeles College
National Institutes of Health
Mayo Clinic
Janssen (Belgium)